The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Highlights•BRAF alterations lead to unbridled activation of the MAPK pathway which can
result in cancer development and progression.•BRAF and MEK inhibitors led to paradigm …

The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Cell-free DNA (cfDNA) sequencing has demonstrated great potential for early cancer
detection. However, most large-scale studies have focused only on either targeted …

Current evaluation of treatment response in solid tumors depends on dynamic changes in
tumor diameters as measured by imaging. However, these changes can only be detected …

Simple Summary In recent years, the genetic landscape of hepatocellular carcinoma (HCC)
has been explored, identifying TERT promoter, CTNNB1, and TP53 as the most frequent …

Over the last decade, great advancements have been made in the field of liquid biopsy
through extensive research and the development of new technologies that facilitate the use …

Rearranged during transfection (RET) is a protooncogene that encodes for receptor tyrosine
kinase with downstream effects on multiple cellular pathways. Activating RET alterations can …

Introduction Considering the growing interest in matched cancer treatment, our aim was to
evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least …